1. Cyhoeddwyd

   Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout

   Hill McManus, D., Marshall, S., Soto, E. & Hughes, D., Medi 2019, Yn: Clinical Pharmacology and Therapeutics. 106, 3, t. 652-660

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Combining model-based clinical trial simulation, pharmacoeconomics and value of information to optimize trial design

   Hill-McManus, D. & Hughes, D., Ion 2021, Yn: CPT: Pharmacometrics & Systems Pharmacology . 10, 1, t. 75-83 9 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data

   Hill-McManus, D. & Hughes, D., Meh 2022, Yn: British Journal of Clinical Pharmacology. 88, 6, t. 2782-2792 11 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development

   Hill-McManus, D., Marshall, S., Liu, J., Willke, R. & Hughes, D., Gorff 2021, Yn: Clinical Pharmacology and Therapeutics. 110, 1, t. 49-63

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Impact of non-adherence and flare resolution on the cost effectiveness of treatments for gout: Application of a linked pharmacometric/pharmacoeconomic model

   Hill-McManus, D., Marshall, S., Soto, E., Lane, S. & Hughes, D., Rhag 2018, Yn: Value in Health. 21, 12, t. 1373-1381

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients

   Holmes, E. A., Morrison, V. L. & Hughes, D., Awst 2016, Yn: British Journal of Clinical Pharmacology. 82, 2, t. 522-531

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   A new taxonomy for describing and defining adherence to medications

   Holmes, E. A., Hughes, D., Morrison, V. L., Vrijens, B., De Geest, S., Hughes, D. A., Prezemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J. K. & Urquhart, J., 1 Mai 2012, Yn: British Journal of Clinical Pharmacology. 73, 5, t. 691-705

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   New advice on switching antiepileptic drugs might be a false economy

   Holmes, E. A., Plumpton, C. O., Hughes, D., Holmes, E., Plumpton, C., Duerden, M., Marson, T. & Hughes, D. A., 16 Rhag 2013, Yn: British Medical Journal. 347

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Predicting Adherence to Medications Using Health Psychology Theories: A Systematic Review of 20 Years of Empirical Research

   Holmes, E. A., Morrison, V. L. & Hughes, D., 8 Rhag 2014, Yn: Value in Health. 17, 8, t. 863-876

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Developing an alternative care pathway for emergency ambulance responses for adults with epilepsy: A Discrete Choice Experiment to understand which configuration service users prefer. Part of the COLLABORATE project

    Holmes, E., Dixon, P., Mathieson, A., Ridsdale, L., Morgan, M., McKinlay, A., Dickson, J., Goodacre, S., Jackson, M., Foster, D., Hardman, K., Bell, S., Marson, A., Hughes, D. & Noble, A. J., Ebr 2024, Yn: Seizure: European Journal of Epilepsy. 118, t. 28-37

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care

    Holmes, E., Harris, S. D., Hughes, A., Craine, N. & Hughes, D., 7 Rhag 2018, Yn: Antibiotics. 7, 4, 19 t., 106.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Wedi ei Dderbyn / Yn y wasg

    A model-based cost-utility analysis of an automated notification system for deteriorating patients on general wards

    Holmes, E., Hughes, D. & Subbe, C., 18 Ebr 2024, (Wedi ei Dderbyn / Yn y wasg) Yn: PLoS ONE. PONE-D-23-27466R2.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

13. Cyhoeddwyd

    Patient preferences for outcomes in clinical trials: implications for medicines optimization

    Holmes, E., Marson, A. G. & Hughes, D., 8 Mai 2017, Yn: Trials. 18 (Suppl 1), O18, t. 192 1 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    Challenges for economic evaluation of strategies to contain antimicrobial resistance

    Holmes, E. & Hughes, D., 27 Medi 2019, Yn: Antibiotics. 8, 4, 8 t., 166.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Patient-focused drug development methods for benefit-risk assessments: A case study using discrete choice experiment for antiepileptic drugs

    Holmes, E. A. F., Plumpton, C., Baker, G. A., Jacoby, A., Ring, A., Williamson, P., Marson, A. & Hughes, D. A., Maw 2019, Yn: Clinical Pharmacology and Therapeutics. 105, 3, t. 672-683 12 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.

    Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Maw 2012, Yn: Pharmacoeconomics.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

17. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

18. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Cyhoeddwyd

    Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

    Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Hyd 2011, Yn: British Medical Journal. 343, t. 1-14

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

21. Cyhoeddwyd

    A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)

    Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, N. V., 9 Ion 2014, Yn: Trials. 15, 14

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    The problem of orphan drugs

    Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Tach 2010, Yn: British Medical Journal. 341, t. 335-341

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

23. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

25. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. Cyhoeddwyd

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

27. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

28. Cyhoeddwyd

    Is exercise effective in promoting mental well-being in older age? A systematic review.

    Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Awst 2010, Yn: Aging and Mental Health. 14, 6, t. 652-669

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

29. Cyhoeddwyd

    Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

    Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

30. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

32. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008

    Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe

33. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

35. Cyhoeddwyd

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

38. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

40. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

41. Cyhoeddwyd

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

42. Cyhoeddwyd

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

43. Cyhoeddwyd

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

44. Cyhoeddwyd

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

45. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

46. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

47. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

48. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

49. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

50. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn